Pregnancy Implantation and Preimplantation Genetic Screening
ATLANTA CENTER FOR REPRODUCTIVE MEDICINE
IS RECRUITING PATIENTS FOR A RESEARCH STUDY EVALUATING PREGNANCY AND IMPLANTATION RATES IN WOMEN UNDERGOING IN VITRO FERTILIZATION (IVF) AND PREIMPLANTATION GENETIC SCREENING (PGS)
IPSO Trial - Impact of Parental SupportTM on pregnancy Outcomes
ACRM is currently recruiting healthy women undergoing In Vitro Fertilization (IVF) between the ages of 35 to 42 years to participate in a randomized study.
The purpose of the study is to determine whether PGS (preimplantation genetic screening) - testing of embryos created during IVF for chromosome abnormalities, prior to transfer to the uterus - improves pregnancy and implantation rates in patients when compared to patients whose embryos are not tested. PGS will be conducted using 24 Chromosome Aneuploidy Screening with Parental SupportTM from Gene Security Network.
If you meet the criteria below, you may be a candidate for this study. To participate in the study you must:
- Be a healthy, pre-menopausal female, 35-42 years of age
- Have a history of less than 3 consecutive miscarriages and no more than one failed IVF cycle
- Agree to use Ferring Pharmaceutical products during stimulation
- Agree to be randomly assigned to either the arm of the study receiving PGS (TEST arm) or the arm receiving no additional testing (CONTROL arm)
Additional screening will be conducted to determine if you are eligible to enroll.
If you qualify and enroll you will receive discounted IVF medications. If you become pregnant during the study, you will receive a small payment for providing information about your pregnancy and birth. If you are assigned to the TEST arm of the study you will receive free PGS.
If you are interested in more information about this research study, please go to www.clinicaltrials.gov or contact:
Atlanta Center for Reproductive Medicine at email@example.com or 678-841-1089.